Alteronol inhibits proliferation in HeLa cells through inducing a G1-phase arrest

Yao, Ying; Zhang, Bo; Chen, Hongmei; Chen, Na; Liu, Liangliang; Wang, Yishan; Li, Changling; Zheng, Qi

doi:10.1111/j.2042-7158.2011.01375.x

Cited by 6 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alteronol is a novel compound isolated and purified form the fermentation products of a microorganism mutation strain, which from the bark of the yew tree in Kunming, China . Recent studies confirmed it has played an antitumour role in prostate cancer, gastric cancer, leukaemia, melanoma and other malignant tumours .…”

Section: Discussionmentioning

confidence: 99%

“…Paclitaxel (PTX) is a kind of natural antitumour drug from the bark of the yew tree, which has unique pharmacological effects and used as the first‐line and second‐line chemotherapy drug for breast cancer, ovarian cancer and non‐small cell lung cancer, as well as it can be used in the treatment of head and neck cancer, oesophageal cancer . Although paclitaxel is sensitive and effective for breast cancer, it has many toxic reactions, such as allergic reaction, myelosuppression and neurotoxicity .…”

Section: Introductionmentioning

confidence: 99%

“…So, to seek a new compound for breast cancer therapy has become an urgent matter. Alteronol, obtaining from the bark of Kunming Zishan through microbial strain, fermentation and purification process, has a similar structure with paclitaxel . In recent years, several studies showed that alteronol inhibits the proliferation of several tumour cells .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Alteronol induces cell cycle arrest and apoptosis via increased reactive oxygen species production in human breast cancer T47D cells

Ren

et al. 2018

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Alteronol induces cell cycle arrest and apoptosis via increased reactive oxygen species production in human breast cancer T47D cells

Ren

et al. 2018

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Alteronol is a novel compound isolated from the fermentation products of a microbial mutant strain in the bark of Taxus chinensis (Pilger) Rehd (Yao et al, 2012). Recently, several studies have shown that alteronol has anti-tumor effects in several types of neoplasms, such as leukemia (Liu Z.Z.…”

Section: Introductionmentioning

confidence: 99%

Alteronol Enhances the Anti-tumor Activity and Reduces the Toxicity of High-Dose Adriamycin in Breast Cancer

Ren

Gong

et al. 2019

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

The first-line chemotherapy drug adriamycin (ADM) is widely used for the treatment of breast cancer, but the acquired drug resistance and the normal tissue toxicity remain clinical challenges. Alteronol has been reported to exert wide-ranging anti-tumor activity. In this study, we firstly examined the synergistic anti-tumor effects and the underlying mechanisms of alteronol combined with ADM in breast cancer. We have found that the combination of alteronol and ADM significantly suppressed the expression levels of the cell cycle-related proteins (CDC2 and Cyclin B1) and induced cell cycle arrest at the G2/M phase, leading to cell proliferation inhibition in breast cancer 4T1 cells. Moreover, co-treatment of alteronol and ADM (i) remarkably activated p38 and JNK kinases, (ii) elevated ROS levels, (iii) triggered mitochondrial dysfunction, (iv) released cytochrome c into the cytoplasm, (v) upregulated apoptosis-related proteins, e.g., cleaved PARP, Bax, and cleaved caspase-3/9, and (vi) downregulated the expression of Bcl-2, followed by apoptosis. Furthermore, our in vivo studies showed that the low-dose combination of alteronol (2 mg/kg) and ADM (1 mg/kg) significantly inhibited tumor growth in tumor bearing mice, and the anti-tumor effect of the combination was the same as that of high-dose ADM (8 mg/kg). In addition, the low-dose combination group showed lower toxicities to major organs than the high-dose ADM group. Taken together, these data demonstrate that the low-dose combination of alteronol and ADM could notably improve the anti-tumor activity and have lower toxicities to major organs than those in high-dose ADM group.

show abstract

“…We have reported that alteronol inhibits HeLa cell proliferation by G1 cell cycle arrest (Yao et al, ). Alternol and alteronol have a similar structure; hence, we hypothesised that alternol elicits a similar effect on cell cycle.…”

Section: Introductionmentioning

confidence: 99%

Alternol induces an S‐phase arrest of melanoma B16F0 cells

Liu

Zhang

Xuan

et al. 2014

Cell Biology International

Self Cite

View full text Add to dashboard Cite

Alternol is a novel compound purified from the fermentation products of a microorganism in the yew tree bark. This study looks at the effects of alternol on the proliferation and cell cycle distribution of mouse melanoma cells. The inhibition of cell proliferation and changes in cell cycle distribution were analysed by sulforhodamine B and flow cytometry assays, respectively. mRNA expression of cyclin A, cyclin-dependent kinase 2 (CDK2), proliferating cell nuclear antigen (PCNA) and CDK inhibitor1A (p21) were measured by real-time reverse transcription PCR (RT-PCR). The protein levels of cyclin A, CDK2 and PCNA were analysed by Western blot analysis. p21 was measured by ELISA. Alternol treatment caused a significant decrease in the proliferation rate of B16F0 and B16F10 cells, which were significantly arrested in S phase, but this treatment had less effect on normal human embryonic kidney 293T cells. The mechanism by which alternol inhibits B16F0 proliferation in vitro may be associated with the inhibition of CDK2 and PCNA, and the activation of p21.

show abstract

Alteronol inhibits proliferation in HeLa cells through inducing a G1-phase arrest

Abstract: Downregulation of the mRNA levels of CDK2, CDK4 and cyclin D1 and upregulation of p21 might be a possible mechanism for the inhibition of proliferation induced by alteronol in HeLa cells.

Cited by 6 publications

References 26 publications

Alteronol induces cell cycle arrest and apoptosis via increased reactive oxygen species production in human breast cancer T47D cells

Alteronol induces cell cycle arrest and apoptosis via increased reactive oxygen species production in human breast cancer T47D cells

Alteronol Enhances the Anti-tumor Activity and Reduces the Toxicity of High-Dose Adriamycin in Breast Cancer

Alternol induces an S‐phase arrest of melanoma B16F0 cells

Contact Info

Product

Resources

About